Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$30.9M
9M shares
52-week range
$2.25 – $7.89
19% from low
Exchange
NASDAQ
CS
Borrow rate
128.03%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $31.2M | $0 | $35.5M | $48.5M | $41.4M | $78.1M | $99.3M |
| Cost of revenue | $21.6M | $0 | $26.5M | $39.1M | $31.1M | $102.1M | $124.6M |
| Gross profit | $9.7M | $0 | $9.0M | $9.4M | $10.3M | −$24.0M | −$25.3M |
| Gross margin | 31.0% | — | 25.5% | 19.3% | 24.9% | -30.8% | -25.4% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$5.3M | −$576.3K | −$13.4M | −$15.1M | −$12.5M | −$61.5M | −$72.4M |
| EBITDA | −$4.7M | $941.6K | −$14.5M | −$56.0M | −$11.5M | −$55.4M | −$74.1M |
| Net income | −$6.7M | $941.6K | −$17.8M | −$61.0M | −$15.8M | −$63.6M | −$89.5M |
| Net margin | -21.6% | — | -50.1% | -125.9% | -38.2% | -81.4% | -90.1% |
| EPS (diluted) | -1.30 | 0.18 | -3.45 | -11.75 | -3.00 | -11.00 | -13.16 |
Annual figures · source: Financial Modeling Prep
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.
www.anghami.comNo one on the platform currently holds ANGH.
No tracked institution reports a position in ANGH as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-08-04 | 1-for-10reverse |
No one on the platform has traded ANGH yet.
| $1M |
| — |
| DLPNDolphin Entertainment Inc. | $1.17 | +2.92% | $15M | — |
| HOFVHall of Fame Resort & Entertainment Company | $0.35 | +0.00% | $2M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at NaN× sales vs its 1.2× historical median P/S.
Fair value ≈ $0.00 · price $3.34 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Losers Today: $LICN $ANGH $BTCT.X $CRMT $SCAG Download this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading
View on StockTwits ↗$ANGH 13D/A filed today: OSN Streaming submitted a preliminary non-binding proposal to acquire remaining Anghami shares for $3.39/share cash.
View on StockTwits ↗$ANGH its still just at $0.54 pre split... for context the 3 share converts that osn amd wbd got were at $2.5 pre split so still some legs in it to run
View on StockTwits ↗$ANGH apparently Shakira posted a link of her world cup song on her social profile to anghami
View on StockTwits ↗$ANGH not chasing, but definitely respecting the move
View on StockTwits ↗$ANGH in 7.88 just before the halt, let's get it to $10! HARD SL 6.5. will move the profits into SPCX
View on StockTwits ↗$CUE Update After a strong run from our $20–$22 entry point to a $32 peak, $CUE is experiencing a healthy pullback. This consolidation is a normal digestion phase for the stock. Quick Stats Previous Entry Zone: $20–$22 Recent High: $32 Status: Healthy Pullback What's coming up soon: 🔹Planned IND submission to the FDA to expand into food allergies (2H 2026). 🔹Upcoming results from the China Phase 2 CSU study. With a strengthened balance sheet and a focus on transformative immunological therapies, the long-term thesis remains intact and the path for potential upside is clear for patient holders. Keep watching the setup. Not financial advice. Trade your plan. Communicated Disclaimer - https://stockresearchtoday.com/cue/ Other biotech's running up: $UBXG $ANGH $BYAH
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.